Clinical Trial Update: MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for MG4101 plus rituximab with lymphodepletion in relapsed/refractory non-Hodgkin lymphoma (B-cell origin) spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• MG4101 (ex vivo expanded allogeneic NK cell therapy)
• Rituximab (rituximab)

Snippet

Sponsor: GC Cell Corporation | Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN